Every Form 4 that Atossa Therapeutics, Inc. (ATOS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ATOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATOS filings page.
Steinhart Richard I reported acquisition or exercise transactions in this Form 4 filing.
Atossa Therapeutics director Richard I. Steinhart received an equity award. He was granted 10,000 shares of common stock in the form of restricted stock units, with no cash price per share reported. Following this grant, he holds 10,000 shares directly.
The footnote explains that each RSU represents a contingent right to receive one share of common stock, and the RSUs will vest on the first anniversary of May 12, 2026. This is a compensation-related award, not an open‑market stock purchase or sale.
Chen Shu-Chih reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. director Shu-Chih Chen reported an equity award and updated holdings. Chen received a grant of 10,000 restricted stock units (RSUs), each representing the right to receive one share of common stock, at a price of $0.0000 per share. The RSUs vest on the first anniversary of May 12, 2026. Following this grant, Chen holds 10,000 common shares directly and 1,483 common shares indirectly through Ensisheim Partners, LLC, where voting and investment power is shared with Dr. Steven C. Quay, and beneficial ownership is disclaimed except to the extent of Chen’s pecuniary interest.
Remmel H. Lawrence reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. director Remmel H. Lawrence reported a compensation-related stock grant. He received 10,000 restricted stock units, each representing one share of common stock at no cash cost. These RSUs vest on the first anniversary of May 12, 2026. After this award, Lawrence directly holds 10,683 shares of common stock, reflecting a relatively small, routine equity grant rather than an open-market purchase.
Finn Jonathan reported acquisition or exercise transactions in this Form 4 filing.
Atossa Therapeutics director Jonathan Finn received an equity grant of 10,000 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and is compensation-related, not an open-market purchase. After the grant, Finn directly holds 11,666 shares. According to the footnote, each RSU represents a contingent right to receive one share of Common Stock, and the RSUs shall vest on the first anniversary of May 12, 2026.
Galli Stephen J reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. director Stephen J. Galli received an award of 10,000 shares of Common Stock in the form of restricted stock units (RSUs) on May 12, 2026. After this grant, he holds 10,006 shares directly. Each RSU represents a contingent right to receive one share of Common Stock and will vest on the first anniversary of May 12, 2026.
Cigler Tessa reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. director Tessa Cigler reported an equity award of 10,000 shares of Common Stock on May 12, 2026. The award is structured as restricted stock units (RSUs), with each RSU representing a contingent right to receive one share of Common Stock.
The RSUs vest on the first anniversary of May 12, 2026, meaning they become deliverable as shares after that date if vesting conditions are satisfied. Following this grant, Cigler is shown as directly holding 10,000 shares of Common Stock.
QUAY STEVEN C reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. President & CEO Steven C. Quay received an equity grant of 65,000 restricted stock units of Common Stock. These RSUs vest in three equal annual installments on the first three anniversaries of March 26, 2026. Following the grant, he directly holds 88,038 shares of Common Stock and has indirect ownership of 1,483 shares through Ensisheim Partners, LLC, an entity he wholly owns with Dr. Shu-Chih Chen. The share counts have been adjusted to reflect a one-for-fifteen reverse stock split of Common Stock that occurred on February 2, 2026.
Daniel Mark James reported acquisition or exercise transactions in this Form 4 filing.
Atossa Therapeutics’ Chief Financial Officer Daniel Mark James received a grant of 63,000 restricted stock units of common stock. The award was granted at no cash cost to him and brings his reported direct holdings to 63,000 shares-equivalent.
The RSUs vest in three equal annual installments on the first three anniversaries of March 26, 2026, meaning the award is structured to retain and incentivize the CFO over multiple years.
Atossa Therapeutics President and CEO Steven C. Quay filed an amended Form 4 updating an equity award reported for January 20, 2026. The filing now shows he acquired 331,674 restricted stock units, each representing one share of common stock, vesting one year after the grant date.
Following the transaction, he holds 345,572 common shares directly and 22,254 shares indirectly through Ensisheim Partners, LLC, which he co-owns with Dr. Shu-Chih Chen. The amendment also reports a grant of 950,000 stock options at an exercise price of $0.603, vesting quarterly over 24 months beginning January 20, 2026.
Atossa Therapeutics President & CEO Steven C. Quay, who also serves as a director, reported new equity awards dated January 20, 2026. He received 325,203 restricted stock units (RSUs), each representing one share of common stock, which will vest one year from the grant date. He was also granted 950,000 stock options with an exercise price of $0.603, vesting quarterly over 24 months following January 20, 2026, contingent on continued service.
Following these awards, Quay directly beneficially owns 339,101 shares of common stock and indirectly holds 22,254 shares through Ensisheim Partners, LLC, an entity he co‑owns with Dr. Shu‑Chih Chen, with shared voting and investment power and a disclaimer of beneficial ownership beyond his pecuniary interest.
Atossa Therapeutics (ATOS) reported an insider equity award on Form 4. The company’s Chief Financial Officer received a stock option grant to purchase 578,000 shares at an exercise price of $1.03 per share, with a transaction date of October 14, 2025.
The options vest as follows: 25% on October 14, 2026, with the remaining 75% vesting in equal quarterly installments over the following three years, subject to continued service. The options expire on October 14, 2035. Ownership is listed as Direct.